{"id":"NCT03099382","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","briefTitle":"Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer","officialTitle":"A Randomized, Open-Label, Active-Controlled, Multi-Center, Phase III Clinical Study of Anti-PD-1 Antibody SHR-1210 vs. Investigator's Choice of Chemotherapy in Subjects With Locally Advanced or Metastatic Esophageal Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-05-05","primaryCompletion":"2019-05-06","completion":"2019-05-06","firstPosted":"2017-04-04","resultsPosted":"2024-01-22","lastUpdate":"2024-01-22"},"enrollment":457,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Esophageal Carcinoma"],"interventions":[{"type":"BIOLOGICAL","name":"camrelizumab","otherNames":["SHR-1210"]},{"type":"DRUG","name":"Docetaxel","otherNames":[]},{"type":"DRUG","name":"Irinotecan","otherNames":[]}],"arms":[{"label":"camrelizumab","type":"EXPERIMENTAL"},{"label":"Investigator's Choice of Standard Therapy","type":"ACTIVE_COMPARATOR"}],"summary":"In this study, participants with advanced or metastatic squamous cell carcinoma of the esophagus that has progressed after first-line standard therapy will be randomized to receive either single agent SHR-1210 or the Investigator's choice of standard therapy with docetaxel or irinotecan. The primary study hypothesis is that treatment with SHR-1210 will prolong overall survival (OS) as compared to treatment with standard therapy.","primaryOutcome":{"measure":"Overall Survival (OS)","timeFrame":"approximately 24 months","effectByArm":[{"arm":"Camrelizumab","deltaMin":8.28,"sd":null},{"arm":"Investigator's Choice of Standard Therapy","deltaMin":6.24,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":2,"countries":["China"]},"refs":{"pmids":["32416073"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":71,"n":228},"commonTop":["Anaemia","Reactive cutaneous capillary endothelial proliferation","White blood cell count decreased","Asthenia","Decreased appetite"]}}